U.S. Markets close in 1 hr 56 mins

Free Pre-Market Technical Recap on Sanofi and Three Additional Drug Makers Stocks

Stock Research Monitor: HRTX, IMNP, and JNJ

LONDON, UK / ACCESSWIRE / July 6, 2018 / If you want a free Stock Review on SNY sign up now at www.wallstequities.com/registration. On Thursday, July 05, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. All sectors ended Thursday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Drug Manufacturers - Major equities this morning: Heron Therapeutics Inc. (NASDAQ: HRTX), Immune Pharmaceuticals Inc. (NASDAQ: IMNP), Johnson & Johnson (NYSE: JNJ), and Sanofi (NYSE: SNY). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Heron Therapeutics

On Thursday, shares in San Diego, California headquartered Heron Therapeutics Inc. recorded a trading volume of 376,033 shares. The stock ended the day flat at $39.55. The Company's shares have gained 17.88% in the last month, 41.76% over the previous three months, and 182.50% in the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 19.93% and 68.95%, respectively. Furthermore, shares of Heron Therapeutics, which engages in developing medicines to address unmet medical needs, have a Relative Strength Index (RSI) of 62.66. Get the full research report on HRTX for free by clicking below at:

www.wallstequities.com/registration/?symbol=HRTX

Immune Pharmaceuticals

Englewood Cliffs, New Jersey headquartered Immune Pharmaceuticals Inc.'s stock finished yesterday's session 1.74% higher at $0.18. A total volume of 272,067 shares was traded. The stock is trading below its 50-day moving average by 28.88%. Furthermore, shares of Immune Pharma, which engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases, have an RSI of 33.65. To experience our free membership services anytime/ anywhere and access the free report on IMNP, click to register at:

www.wallstequities.com/registration/?symbol=IMNP

Johnson & Johnson

At the close of trading on Thursday, shares in New Brunswick, New Jersey-based Johnson & Johnson saw a rise of 1.81%, ending the day at $124.93. The stock recorded a trading volume of 6.46 million shares. The Company's shares have advanced 2.84% in the last month. The stock is trading above its 50-day moving average by 1.32%. Moreover, shares of Johnson & Johnson, which together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide, have an RSI of 61.08.

On June 27th, 2018, research firm Bernstein initiated a 'Market Perform' rating on the Company's stock, with a target price of $129 per share. Join our big investor community at Wall St. Equities today and get your free report on JNJ at:

www.wallstequities.com/registration/?symbol=JNJ

Sanofi

Paris, France headquartered Sanofi's shares ended the day 3.37% higher at $42.04 with a total trading volume of 4.31 million shares, which was above their three months average of 2.02 million shares. The stock has gained 9.34% in the last month. The Company's shares are trading above their 50-day moving average by 7.56%. Additionally, shares of Sanofi, which provides therapeutic solutions, have an RSI of 69.47. Know more about SNY in our free research coverage at:

www.wallstequities.com/registration/?symbol=SNY

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities